BioLife Solutions Inc - Asset Resilience Ratio
BioLife Solutions Inc (BLFS) has an Asset Resilience Ratio of 13.05% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BioLife Solutions Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2025)
This chart shows how BioLife Solutions Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BioLife Solutions Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down BioLife Solutions Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BLFS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $58.42 Million | 13.05% |
| Total Liquid Assets | $58.42 Million | 13.05% |
Asset Resilience Insights
- Moderate Liquidity: BioLife Solutions Inc has 13.05% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
BioLife Solutions Inc Industry Peers by Asset Resilience Ratio
Compare BioLife Solutions Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
Visco Vision Inc.
TW:6782 |
Medical Instruments & Supplies | 0.98% |
|
QITIAN Technology Group Co Ltd
SHE:300061 |
Medical Instruments & Supplies | 0.00% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
Annual Asset Resilience Ratio for BioLife Solutions Inc (1993–2025)
The table below shows the annual Asset Resilience Ratio data for BioLife Solutions Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.77% | $55.89 Million | $405.88 Million | +11.47pp |
| 2024-12-31 | 2.30% | $9.20 Million | $399.49 Million | -1.64pp |
| 2023-12-31 | 3.95% | $16.29 Million | $412.71 Million | -5.66pp |
| 2022-12-31 | 9.61% | $43.26 Million | $450.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $554.29 Million | -- |
| 2020-12-31 | 2.50% | $5.87 Million | $234.83 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $12.14 Million | -- |
| 2016-12-31 | 20.83% | $1.65 Million | $7.93 Million | +7.48pp |
| 2015-12-31 | 13.35% | $1.65 Million | $12.37 Million | -32.69pp |
| 2014-12-31 | 46.04% | $7.40 Million | $16.07 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $3.35 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.17 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.66 Million | -- |
| 1996-12-31 | 1.82% | $110.15K | $6.04 Million | +0.63pp |
| 1995-12-31 | 1.19% | $100.31K | $8.40 Million | 0.00pp |
| 1994-12-31 | 1.19% | $100.31K | $8.40 Million | +0.09pp |
| 1993-12-31 | 1.10% | $100.31K | $9.10 Million | -- |
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, inc… Read more